Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PREDNISONE vs A-HYDROCORT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Agonist at glucocorticoid receptors, leading to altered gene transcription that results in anti-inflammatory and immunosuppressive effects, including suppression of cytokines, prostaglandins, and leukotrienes.
Hydrocortisone is a corticosteroid hormone that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation, inhibit immune response, and regulate metabolism.
Allergic reactions (severe or incapacitating),Asthma,Chronic obstructive pulmonary disease (COPD) exacerbation,Collagen diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis),Dermatologic diseases (e.g., pemphigus, severe erythema multiforme),Endocrine disorders (e.g., adrenocortical insufficiency, congenital adrenal hyperplasia),Gastrointestinal diseases (e.g., ulcerative colitis, Crohn's disease),Hematologic disorders (e.g., autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura),Neoplastic diseases (e.g., leukemias, lymphomas),Nephrotic syndrome,Ophthalmic diseases (e.g., severe allergic conjunctivitis, keratitis),Organ transplantation (immunosuppression),Respiratory diseases (e.g., sarcoidosis, berylliosis),Rheumatic disorders (e.g., acute gouty arthritis, psoriatic arthritis),Tuberculous meningitis (with appropriate antituberculous therapy)
Adrenocortical insufficiency (primary and secondary),Congenital adrenal hyperplasia,Inflammatory conditions (e.g., rheumatoid arthritis, ulcerative colitis),Allergic reactions (severe),Asthma exacerbations,Dermatologic disorders (topical use),Ophthalmic inflammation (ophthalmic use)
5-60 mg orally once daily or divided twice daily; for acute indications, initial dose 5-60 mg/day; for chronic conditions, lowest effective dose; route: oral, intravenous, intramuscular.
Adrenal insufficiency: oral 20-30 mg/day in divided doses; inflammatory conditions: 5-60 mg/day oral; IV/IM: hydrocortisone sodium succinate 50-100 mg every 4-6 hours.
Terminal half-life: 2-3 hours (plasma); clinical effects persist for 12-36 hours due to intracellular actions and active metabolite prednisolone (half-life 3-4 hours).
Terminal half-life: 1.5-2 hours (cortisol); clinical effect persists 8-12 hours due to glucocorticoid receptor binding
Hepatic, primarily via CYP3A4-mediated 6β-hydroxylation; also reduced by 20-ketosteroid reductases. Prednisone is a prodrug converted to active metabolite prednisolone.
Primarily hepatic via CYP3A4 and other CYP450 enzymes, with reduction in the A-ring to inactive metabolites (e.g., tetrahydrocortisol).
Renal: <10% as unchanged drug; hepatic metabolism to inactive glucuronide and sulfate conjugates; fecal: ~20-30% via biliary elimination.
Renal (primarily as metabolites, <1% unchanged); biliary/fecal (<5%)
Prednisone: 70-90% bound to albumin and corticosteroid-binding globulin (CBG); prednisolone: 60-70% bound.
90-95% bound to corticosteroid-binding globulin (CBG) and albumin
Vd: 0.5-1.0 L/kg; distributes widely, crosses placenta and enters breast milk; apparent Vd larger with hyperthyroidism.
0.5-0.8 L/kg; represents distribution into total body water, higher in obesity
Oral: 70-80% (active prednisolone after hepatic conversion); IM: ~100%.
Oral: 96% (well absorbed); IM/IV: 100%; topical: minimal systemic absorption (<1% with intact skin)
No dose adjustment required for renal impairment; consider alternative corticosteroid in severe renal disease if fluid retention is a concern.
No specific adjustment required; monitor fluid/electrolytes in severe renal impairment.
Child-Pugh A: no adjustment. Child-Pugh B or C: use with caution; dose reduction may be considered due to decreased clearance; monitor for adverse effects.
Dose reduction may be necessary in severe hepatic impairment; caution as metabolism is hepatic.
0.1-2 mg/kg/day orally divided 1-4 times daily; maximum 60 mg/day; use lowest effective dose; for acute asthma, 1-2 mg/kg/day for 3-5 days.
Doses are weight-based; for adrenal insufficiency: 0.5-0.75 mg/kg/day in divided doses; for anti-inflammatory: 0.5-10 mg/kg/day.
Start at lower end of dosing range (5-7.5 mg/day) due to increased risk of osteoporosis, hyperglycemia, and infections; monitor glucose and bone density; taper slowly to avoid adrenal suppression.
Use lowest effective dose; monitor for osteoporosis, hypertension, and glucose intolerance.
None
None.
Adrenal suppression and HPA axis suppression with prolonged therapy,Increased risk of infections,Exacerbation of systemic fungal infections,Masking of signs of infection,Osteoporosis with long-term use,Gastrointestinal perforation (especially in patients with certain GI disorders),Kaposi sarcoma reported,Cardiovascular effects (hypertension, fluid retention),Behavioral disturbances (euphoria, depression, psychosis),Posterior subcapsular cataracts and glaucoma,Thromboembolism risk,Vaccine response may be diminished; live vaccines contraindicated
Immunosuppression and increased infection risk,Adrenal suppression with prolonged use,Cushing's syndrome with chronic use,Osteoporosis with long-term use,GI perforation risk in inflammatory bowel disease,Growth suppression in children,Fetal harm (category C),Ocular effects (cataracts, glaucoma),Fluid and electrolyte disturbances
Systemic fungal infections,Hypersensitivity to prednisone or any component,Administration of live or live attenuated vaccines (due to immunosuppression)
Systemic fungal infections,Hypersensitivity to hydrocortisone or any component,Administration of live or live-attenuated vaccines (relative),Herpes simplex keratitis (topical ophthalmic use),Peptic ulcer disease (relative),Uncontrolled hypertension (relative)
Avoid grapefruit juice as it may increase prednisone levels. Limit high-sodium foods to prevent fluid retention. Increase calcium and vitamin D intake to counteract bone loss. Avoid alcohol due to added GI irritation risk.
No specific food interactions. However, high-sodium foods may exacerbate fluid retention; a low-sodium diet is recommended if edema occurs. Grapefruit juice does not significantly affect hydrocortisone. Avoid alcohol due to additive gastric irritation.
First trimester: Increased risk of cleft lip/palate (odds ratio 1.3-3.4). Second/third trimester: Fetal growth restriction, adrenal suppression, preterm delivery. Chronic use: Dose-dependent fetal hypothalamic-pituitary-adrenal axis suppression.
Hydrocortisone is a corticosteroid. Use during first trimester is associated with increased risk of oral clefts (odds ratio 1.5-3.0). Second and third trimester use may cause fetal adrenal suppression, growth restriction, and premature birth. Risk of premature rupture of membranes and intrauterine growth restriction increases with prolonged use.
Prednisone enters breast milk in low concentrations (M/P ratio ~0.25-0.5). Maternal doses ≤20 mg/day produce negligible infant exposure. Higher doses: Avoid breastfeeding for 4 hours after dose. Monitor infant for growth and adrenal suppression.
Hydrocortisone is excreted into breast milk in low concentrations. M/P ratio approximately 0.4-1.0. Doses up to 20 mg/day are considered compatible with breastfeeding. Higher doses may suppress infant adrenal function; monitor infant for growth and adrenal suppression.
Minimal pharmacokinetic changes (slight increase in clearance). No routine dose adjustment needed. For acute indications, use lowest effective dose. For chronic conditions, increase dose may be needed in third trimester due to disease flare; taper postpartum.
Due to increased clearance and protein binding changes, doses may need to be increased by 50-100% in the second and third trimesters. Monitor clinical response and adjust dose accordingly. Stress doses (e.g., 50-100 mg IV) should be given during labor and delivery.
Prednisone is a prodrug converted to prednisolone; use prednisolone in severe hepatic impairment. Taper dose after prolonged use (≥3 weeks) to avoid adrenal crisis. Morning dosing mimics cortisol rhythm and reduces insomnia. Monitor for hyperglycemia, osteoporosis, avascular necrosis, and immunosuppression. Do not give live vaccines during therapy.
For acute adrenal insufficiency, give IV bolus of 100 mg hydrocortisone followed by 100 mg every 8 hours. Taper to oral replacement over days. In septic shock, stress-dose hydrocortisone (200 mg/day) may be used if vasopressor-dependent. Monitor for hyperglycemia, hypokalemia, and immunosuppression. Abrupt discontinuation can cause adrenal crisis.
Take with food or milk to reduce stomach upset.,Do not stop abruptly; follow a tapering schedule from your doctor.,Notify your doctor if you experience fever, unusual bleeding, or weight gain.,Avoid live vaccines (e.g., MMR, nasal flu) while on prednisone.,Carry a steroid alert card or wear a medical ID bracelet.
Take exactly as prescribed; do not stop suddenly without doctor's guidance.,Carry a medical alert card or bracelet indicating you take hydrocortisone.,Report signs of adrenal crisis: severe weakness, dizziness, nausea, vomiting, abdominal pain.,During illness or stress (e.g., surgery, infection), dose may need temporary increase; contact your doctor.,Avoid live vaccines during therapy.,Monitor for weight gain, swelling, mood changes, or high blood sugar symptoms (increased thirst, urination).
"The combination of Droxicam, a nonsteroidal anti-inflammatory drug (NSAID) with potent COX-1/COX-2 inhibition, and the corticosteroid Prednisone results in an additive risk of gastrointestinal (GI) mucosal injury and bleeding. NSAIDs suppress protective prostaglandin synthesis in the gastric mucosa via COX-1 inhibition, while corticosteroids further impair mucosal defense and repair mechanisms, increasing the likelihood of peptic ulceration, GI perforation, and hemorrhage. Patients, particularly the elderly or those with prior GI disease, face a significantly elevated risk of serious adverse outcomes including upper GI bleeding and perforation."
"Cabergoline, a dopamine receptor agonist, can cause valvular heart disease due to its agonistic activity at serotonin 5-HT2B receptors on cardiac valves, leading to fibrotic changes. Prednisone, a corticosteroid, may potentiate this risk by suppressing inflammatory responses that could otherwise mitigate fibrotic progression, and by inducing catabolic effects that may exacerbate tissue vulnerability. Concurrent use may therefore increase the severity and progression of valvulopathy and other fibrotic complications."
"Concomitant use of Suprofen, a nonsteroidal anti-inflammatory drug (NSAID), with Prednisone, a corticosteroid, increases the risk of gastrointestinal (GI) adverse effects, including ulceration, bleeding, and perforation. This additive effect results from synergistic inhibition of prostaglandin-mediated protective mechanisms in the gastric mucosa, as both drug classes suppress COX enzymes and reduce mucosal defense. Patients, especially the elderly or those with a history of peptic ulcer disease, are at heightened risk for serious GI complications."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PREDNISONE vs A-HYDROCORT, answered by our medical review team.
PREDNISONE is a Corticosteroid that works by Agonist at glucocorticoid receptors, leading to altered gene transcription that results in anti-inflammatory and immunosuppressive effects, including suppression of cytokines, prostaglandins, and leukotrienes.. A-HYDROCORT is a Corticosteroid that works by Hydrocortisone is a corticosteroid hormone that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation, inhibit immune response, and regulate metabolism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PREDNISONE and A-HYDROCORT depend on the specific clinical indication. These are both Corticosteroid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PREDNISONE is: 5-60 mg orally once daily or divided twice daily; for acute indications, initial dose 5-60 mg/day; for chronic conditions, lowest effective dose; route: oral, intravenous, intramuscular.. The standard adult dose of A-HYDROCORT is: Adrenal insufficiency: oral 20-30 mg/day in divided doses; inflammatory conditions: 5-60 mg/day oral; IV/IM: hydrocortisone sodium succinate 50-100 mg every 4-6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PREDNISONE and A-HYDROCORT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PREDNISONE is classified as Category D/X. First trimester: Increased risk of cleft lip/palate (odds ratio 1.3-3.4). Second/third trimester: Fetal growth restriction, adrenal suppression, preterm delivery. Chronic use: Dose. A-HYDROCORT is classified as Category C. Hydrocortisone is a corticosteroid. Use during first trimester is associated with increased risk of oral clefts (odds ratio 1.5-3.0). Second and third trimester use may cause fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.